This article was first published by The Times of Israel and is re-posted with permission.
The world’s first clinical trial for a coronavirus drug made from antibodies got off to a promising start in Jerusalem, with all three patients involved released from the hospital days after receiving it.
The patients were in moderate condition, with COVID-19-induced pneumonia, when given the drug, manufactured from antibodies found in the plasma of recovered coronavirus patients, earlier this week.
The response was, in my eyes, it was almost a miracle — they received it and they are now home,” said Zeev Rothstein, director of Hadassah Medical Center in Jerusalem, which worked with the biopharmaceutical firm Kamada to develop the drug, and is now running the clinical trial.
To read the full article, click here.